Relationship between accessory renal arteries and resistant hypertension: A cohort study.


Journal

Journal de medecine vasculaire
ISSN: 2542-4513
Titre abrégé: J Med Vasc
Pays: France
ID NLM: 101709200

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 26 12 2022
accepted: 20 03 2023
medline: 1 5 2023
pubmed: 30 4 2023
entrez: 29 4 2023
Statut: ppublish

Résumé

Resistant hypertension (RHT) is a major health care concern affecting 20 to 30% of hypertensive patients and increasing cardiovascular risk. Recent renal denervation trials have suggested a high prevalence of accessory renal arteries (ARA) in RHT. Our objective was to compare the prevalence of ARA in RHT vs. non-resistant hypertension (NRHT). Eighty-six patients with essential hypertension who benefited from an abdominal CT-scan or MRI during their initial workup were retrospectively recruited in 6 French ESH (European Society of Hypertension) centers. At the end of a follow-up period of at least 6 months, patients were classified between RHT or NRHT. RHT was defined as uncontrolled blood pressure despite the optimal doses of three antihypertensive agents of which one is a diuretic or similar, or controlled by ≥ 4 medications. Blinded independent central review of all radiologic renal artery charts was performed. Baseline characteristics were: age 50±15 years, 62% males, BP 145±22/87±13mmHg. Fifty-three (62%) patients had RHT and 25 (29%) had at least one ARA. Prevalence of ARA was comparable between RHT (25%) and NRHT patients (33%, P=0.62), but there were more ARA per patient in NRHT (2±0.9) vs. RHT (1.3±0.5, P=0.05), and renin levels were higher in ARA group (51.6±41.7 mUI/L vs. 20.4±25.4 mUI/L, P=0.001). ARA were similar in diameter or length between the 2 groups. In this retrospective series of 86 essential hypertension patients, we found no difference in the prevalence of ARA in RHT and NRHT. More comprehensive studies are needed to answer this question.

Sections du résumé

BACKGROUND BACKGROUND
Resistant hypertension (RHT) is a major health care concern affecting 20 to 30% of hypertensive patients and increasing cardiovascular risk. Recent renal denervation trials have suggested a high prevalence of accessory renal arteries (ARA) in RHT. Our objective was to compare the prevalence of ARA in RHT vs. non-resistant hypertension (NRHT).
METHODS METHODS
Eighty-six patients with essential hypertension who benefited from an abdominal CT-scan or MRI during their initial workup were retrospectively recruited in 6 French ESH (European Society of Hypertension) centers. At the end of a follow-up period of at least 6 months, patients were classified between RHT or NRHT. RHT was defined as uncontrolled blood pressure despite the optimal doses of three antihypertensive agents of which one is a diuretic or similar, or controlled by ≥ 4 medications. Blinded independent central review of all radiologic renal artery charts was performed.
RESULTS RESULTS
Baseline characteristics were: age 50±15 years, 62% males, BP 145±22/87±13mmHg. Fifty-three (62%) patients had RHT and 25 (29%) had at least one ARA. Prevalence of ARA was comparable between RHT (25%) and NRHT patients (33%, P=0.62), but there were more ARA per patient in NRHT (2±0.9) vs. RHT (1.3±0.5, P=0.05), and renin levels were higher in ARA group (51.6±41.7 mUI/L vs. 20.4±25.4 mUI/L, P=0.001). ARA were similar in diameter or length between the 2 groups.
CONCLUSIONS CONCLUSIONS
In this retrospective series of 86 essential hypertension patients, we found no difference in the prevalence of ARA in RHT and NRHT. More comprehensive studies are needed to answer this question.

Identifiants

pubmed: 37120265
pii: S2542-4513(23)00028-7
doi: 10.1016/j.jdmv.2023.03.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

18-23

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Auteurs

Valentin Maisons (V)

Club des jeunes hypertensiologues, France; Service de néphrologie, CHU de Tours, Tours, France; Inserm U1246 SPHERE, université de Nantes, université de Tours, Tours, France. Electronic address: valentin.maisons@etu.univ-tours.fr.

Sylvain Le Jeune (S)

Club des jeunes hypertensiologues, France; Service de médecine interne et vasculaire, CHU d'Avicenne, AP-HP, Bobigny, France. Electronic address: sylvain.le-jeune@aphp.fr.

Nicolas Barber-Chamoux (N)

Club des jeunes hypertensiologues, France; Service de cardiologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France. Electronic address: nbarber-chamoux@chu-clermontferrand.fr.

Fanny Boudghene-Stambouli (F)

Club des jeunes hypertensiologues, France; Service de cardiologie, polyclinique Saint-Laurent, Rennes, France. Electronic address: fanny.boudghene@gmail.com.

Marie Brucker (M)

Club des jeunes hypertensiologues, France; Service de néphrologie, centre hospitalier de Valence, Valence, France. Electronic address: mbrucker@ch-valence.fr.

Pascal Delsart (P)

Club des jeunes hypertensiologues, France; Service de médecine vasculaire et HTA, CHU de Lille, Lille, France. Electronic address: pascal.delsart@chru-lille.fr.

Marilucy Lopez-Sublet (M)

Club des jeunes hypertensiologues, France; Service de médecine interne et vasculaire, CHU d'Avicenne, AP-HP, Bobigny, France; Inserm U942 MASCOT, université Paris Nord, Paris 13, France; FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. Electronic address: marilucy.lopez-sublet@aphp.fr.

Laurence Perez (L)

Club des jeunes hypertensiologues, France; Service de cardiologie, clinique d'Occitanie, Muret, France. Electronic address: laurenceperez31@hotmail.com.

Ibtissem Radhouani (I)

Service de radiologie, CHU d'Avicenne, AP-HP, Bobigny, France. Electronic address: ibtissem_radhouani@yahoo.com.

Philippe Sosner (P)

Club des jeunes hypertensiologues, France; Mon Stade, maison sport-santé, Paris, France. Electronic address: p.sosner@gmail.com.

Bénédicte Sautenet (B)

Club des jeunes hypertensiologues, France; Service de néphrologie, CHU de Tours, Tours, France; Inserm U1246 SPHERE, université de Nantes, université de Tours, Tours, France; FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. Electronic address: benedicte.sautenet@univ-tours.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH